HOPO 14-1, an Oral Actinide Chelator: A Phase 1 Nonrandomized Clinical Trial.

Single oral doses of HOPO 14-1 up to 7500 mg in 42 healthy adults showed no serious adverse events or dose-limiting toxic effects.

• Why it matters: Existing FDA-approved actinide chelators require intravenous access or supervised inhalation and cover limited radionuclides, leaving a gap for a deployable, broad-spectrum option.
• What they did: In a phase 1 nonrandomized trial at one US site, 42 healthy adults received one oral dose at 1 of 7 levels (100–7500 mg), with safety follow-up for 14 days and plasma PK plus cumulative urinary and fecal excretion.
• The result: HOPO 14-1 was rapidly absorbed (median time to maximum concentration 0.86–1.90 hours) with dose-dependent, more-than-proportional exposure increases; fecal excretion dominated and gastrointestinal events (e.g., diarrhea 31%) defined tolerability at the highest doses.

AI summary of the abstract · may contain errors · not medical advice · read the paper.